The World’s Only Bioprosthetic Auto-regulated Artificial Heart: From Total Artif...
The World’s Only Bioprosthetic Auto-regulated Artificial Heart: From Total Artificial Heart (TAH) to Physiologic Heart Replacement Therapy (PHRT)
At Carmat we have designed and developed Aeson®, the world’s most advanced total artificial heart (TAH), aiming to fulfill an unmet medical need by providing a credible therapeutic alternative to heart transplants for people suffe...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
ArtOfHeart
The first Total Artificial Heart (TAH) that truly mimics the...
38M€
Cerrado
BloodTurbine
Fully implantable patient specific Artificial Hearts without...
150K€
Cerrado
NeuHeart
A neuroprosthesis to restore the vagal cardiac closed loop c...
5M€
Cerrado
LIFEVALVE
Living autologous heart valves for minimally invasive implan...
16M€
Cerrado
HD4HF
Heart Damper a revolutionary device for Heart Failure
71K€
Cerrado
Información proyecto Aeson®
Duración del proyecto: 17 meses
Fecha Inicio: 2023-04-06
Fecha Fin: 2024-09-30
Líder del proyecto
CARMAT
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
12M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
At Carmat we have designed and developed Aeson®, the world’s most advanced total artificial heart (TAH), aiming to fulfill an unmet medical need by providing a credible therapeutic alternative to heart transplants for people suffering from end-stage biventricular heart failure. Aeson® is an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The device is electro-hydraulically driven with a shape close to that of a human heart. Once the Aeson® is powered, it mimics the action of a normal heart, providing mechanical circulatory support and restoring normal blood flow through the body.
Aeson® differs from other existing artificial hearts (or TAH – total artificial hearts) in its unique combination of three features: pulsatility, autoregulation and hemocompatibility. With Aeson®, Carmat is creating a new therapeutic class of physiologic heart replacement therapy (PHRT).